StockData
Integra LifeSciences Holdings Corp logo

Integra LifeSciences Holdings Corp (IART) stock

IARTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 23, 2026Score 9/308% below fair value
$13.55−0.43 (-3.08%)

Close on Nov 17, 2026Market cap $1.05BP/E 79.7Yield –

Earnings

Integra LifeSciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$411.20M
+2.3% on a year earlier
Adjusted earnings per diluted share, Q3 FY2026
$0.59
$0.54 a year earlier
Latest guidance
Issued
Oct 21, 2026 · 7 items

Quarterly results

Revenue and earnings per share from each of Integra LifeSciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 21, 2026before the open$411.20M+2.3%$0.19$0.59Release
Q2 FY2026ended Jun 30, 2026Jul 29, 2026before the open$418.80M+0.8%$0.06$0.56Release
Q1 FY2026ended Mar 31, 2026May 5, 2026before the open$391.90M+2.4%-$0.06$0.54Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$434.90M-1.7%-$0.02$0.83Release
Q3 FY2025ended Sep 30, 2025Oct 30, 2025before the open$402.10M+5.6%-$0.07$0.54Release
Q2 FY2025ended Jun 30, 2025Jul 31, 2025before the open$415.60M-0.6%-$6.31$0.45Release
Q1 FY2025ended Mar 31, 2025May 5, 2025before the open$382.70M+3.7%-$0.33$0.41Release
Q4 FY2024ended Dec 31, 2024Feb 25, 2025before the open$442.60M+11.5%$0.25$0.97Release
Q3 FY2024ended Sep 30, 2024Nov 4, 2024before the open$380.80M-0.4%-$0.14$0.41Release
Q2 FY2024ended Jun 30, 2024Jul 29, 2024before the open$418.20M+9.7%-$0.16$0.63Release
Q1 FY2024ended Mar 31, 2024May 6, 2024before the open$368.90M-3.1%-$0.04$0.55Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Integra LifeSciences's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
organic declinenon-GAAPQ4 FY2026-5.1% – -0.4%–NewOct 21, 2026
reported revenuesGAAPQ4 FY2026$413.00M – $433.00M–NewOct 21, 2026
adjusted earnings per diluted sharenon-GAAPQ4 FY2026$0.61 – $0.71–NewOct 21, 2026
organic growthnon-GAAPFY2026-0.3% – +0.9%–NewOct 21, 2026
organic growthnon-GAAPFY2026+0.8% – +3.3%+0.8% – +3.3%ReaffirmedMay 5, 2026
reported growthFY2026+1.6% – +4.1%+1.6% – +4.1%ReaffirmedMay 5, 2026
reported revenue outlookGAAPFY2026$1.65B – $1.70B–NewJul 29, 2026
revenue guidanceFY2026$1.66B – $1.70B$1.66B – $1.70BReaffirmedMay 5, 2026
revenuesGAAPFY2026$1.63B – $1.65B–NewOct 21, 2026
adjusted earnings per diluted sharenon-GAAPFY2026$2.30 – $2.40–NewOct 21, 2026
adjusted earnings per sharenon-GAAPFY2026$2.40 – $2.50$2.40 – $2.50ReaffirmedJul 29, 2026
operating cash flowGAAPFY2026$190.00M – $200.00M–NewOct 21, 2026
organic revenue growthnon-GAAPFY2026+0.8% – +3.3%–NewJul 29, 2026

Guidance vs results

The last range Integra LifeSciences gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026adjusted EPS$0.53 – $0.61$0.59Within range
Q3 FY2026Revenue$410.00M – $425.00M$411.20MWithin range
Q2 FY2026adjusted EPS$0.44 – $0.52$0.56Above range
Q2 FY2026Revenue$410.00M – $425.00M$418.80MWithin range
Q2 FY2026Revenue growth-1.3% – +2.3%+0.77%Within range
Q1 FY2026Adjusted earnings per diluted share$0.37 – $0.45$0.54Above range
Q1 FY2026Revenue$375.00M – $390.00M$391.90MAbove range
Q1 FY2026Revenue growth-2% – +1.9%+2.4%Above range
FY2025adjusted EPS$2.19 – $2.24$2.23Σ4QWithin range
FY2025Revenue$1.62B – $1.64B$1.64BΣ4QWithin range
FY2025Revenue growth+0.6% – +1.8%+1.54%Σ4QWithin range
Q4 FY2025adjusted EPS$0.79 – $0.84$0.83Within range

Guidance history

Every forecast Integra LifeSciences put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 21, 2026adjusted earnings per diluted shareQ4 FY2026$0.61 – $0.71New
Oct 21, 2026adjusted earnings per diluted shareFY2026$2.30 – $2.40New
Oct 21, 2026operating cash flowFY2026$190.00M – $200.00MNew
Oct 21, 2026organic declineQ4 FY2026-5.1% – -0.4%New
Oct 21, 2026reported revenuesQ4 FY2026$413.00M – $433.00MNew
Oct 21, 2026organic growthFY2026-0.3% – +0.9%New
Oct 21, 2026revenuesFY2026$1.63B – $1.65BNew
Jul 29, 2026adjusted earnings per shareFY2026$2.40 – $2.50Reaffirmed
Jul 29, 2026adjusted EPSQ3 FY2026$0.53 – $0.61New
Jul 29, 2026organic revenue growthFY2026+0.8% – +3.3%New
Jul 29, 2026reported growthQ3 FY2026+2% – +5.7%New
Jul 29, 2026organic growthQ3 FY2026+1.9% – +5.7%New
Jul 29, 2026reported revenue outlookFY2026$1.65B – $1.70BNew
Jul 29, 2026reported revenuesQ3 FY2026$410.00M – $425.00MNew
May 5, 2026adjusted EPSFY2026$2.40 – $2.50Raised
May 5, 2026adjusted EPSQ2 FY2026$0.44 – $0.52New
May 5, 2026reported growthFY2026+1.6% – +4.1%Reaffirmed
May 5, 2026organic growthFY2026+0.8% – +3.3%Reaffirmed
May 5, 2026revenue guidanceFY2026$1.66B – $1.70BReaffirmed
May 5, 2026reported growthQ2 FY2026-1.3% – +2.3%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Integra LifeSciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Results
  5. Update
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Update
  15. Results

See a number that looks wrong?